Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT: NCT04367675 · ACTIVE_NOT_RECRUITING

NCT IDNCT04367675
StatusACTIVE_NOT_RECRUITING
Start Date2021-04-20
Completion2027-03
SponsorAbramson Cancer Center at Penn Medicine (OTHER)
First posted
Last updated

Brief Summary

The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.

Frequently Asked Questions

What is INO 5401 Vaccination in BRCA1/2 Mutation Carriers?

INO 5401 Vaccination in BRCA1/2 Mutation Carriers is a clinical trial registered under NCT04367675. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04367675?

The current status of NCT04367675 (INO 5401 Vaccination in BRCA1/2 Mutation Carriers) is: ACTIVE_NOT_RECRUITING.

When did INO 5401 Vaccination in BRCA1/2 Mutation Carriers start?

INO 5401 Vaccination in BRCA1/2 Mutation Carriers started on 2021-04-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑